Abata Therapeutics

Clinical Scientist, Clinical Development

Remote

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess an advanced degree in life sciences, such as a PhD, PharmD, or a related field, and demonstrate a strong understanding of clinical trial methodologies and regulatory requirements. They should have at least three years of experience in clinical study design, data analysis, data review, and interpretation, along with good written and verbal communication skills.

Responsibilities

The Clinical Scientist will contribute to the development of clinical trial protocols, monitor clinical trial data at study sites ensuring adherence to protocols and GCP guidelines, perform data review and reconciliation, review clinical data to assess safety and efficacy, support the development of clinical documents, maintain knowledge of the therapeutic area and disease state, assess clinical data for safety concerns, conduct literature reviews, and collaborate closely with cross-functional teams including clinical operations, regulatory affairs, medical affairs, biometrics, and project management to ensure data integrity during the clinical development process.

Skills

Clinical trial execution
Data review
Protocol development
Study implementation
Data documentation
Cross-functional collaboration

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI